Skip to main content

PTCT

Stock
Health Care
Biotechnology

Performance overview

PTCT Price
Price Chart

Forward-looking statistics

Beta
1.21
Risk
56.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$2.8B

Fundamentals

Enterprise value$4.3B
Revenue$1.8B
Revenue per employee
Profit margin33.55%
Debt to equity-13.39

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$6.51
Dividend per share
Revenue per share$22.95
Avg trading volume (30 day)$50M
Avg trading volume (10 day)$58M
Put-call ratio

Macro factor sensitivity

Growth-1.1
Credit+6.4
Liquidity+1.5
Inflation-5.8
Commodities-2.3
Interest Rates-1.9

Valuation

Dividend yield0.00%
PEG Ratio-13.33
Price to sales2.19
P/E Ratio-13.33
Enterprise Value to Revenue2.44
Price to book-20.42

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy

PTC Therapeutics (PTCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (June 6, 2025)
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

PTC Therapeutics, Inc. PTCT on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington's disease (HD) patients.

Benzinga (May 5, 2025)
Vaccine stocks fall following FDA resignation

Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.

CNBC Television (March 31, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free